Research location

Marlton

New Jersey, United States

Published trials234

Site observations236

Linked trials published234

Page2 / 5

Research activity in Marlton

New Jersey, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 234 trials and 236 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Marlton

234 linked trials · page 2 of 5

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005NCT05779241 · 2023-04-13 · 1 site observation

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of SchizophreniaNCT05838625 · 2023-03-31 · 1 site observation

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaNCT05693935 · 2023-01-24 · 1 site observation

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05595642 · 2022-12-29 · 1 site observation

ACTIVE_NOT_RECRUITING

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's DiseaseNCT05644977 · 2022-12-02 · 1 site observation

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation

ACTIVE_NOT_RECRUITING

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsNCT05458102 · 2022-08-19 · 1 site observation

A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)NCT05406440 · 2022-07-12 · 1 site observation

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227703 · 2022-07-05 · 1 site observation

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderNCT05376150 · 2022-05-19 · 1 site observation

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)NCT05136690 · 2022-04-27 · 1 site observation

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyNCT05211947 · 2022-03-21 · 1 site observation

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With SchizophreniaNCT05245539 · 2022-01-24 · 1 site observation

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTNNCT05198674 · 2021-10-20 · 1 site observation

ACTIVE_NOT_RECRUITING

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable SchizophreniaNCT04972227 · 2021-09-10 · 1 site observation

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive MedicationNCT04937829 · 2021-07-20 · 1 site observation

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)NCT04820309 · 2021-06-02 · 2 site observations

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.NCT04865835 · 2021-05-12 · 1 site observation

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of HyperkalaemiaNCT04864795 · 2021-04-19 · 1 site observation

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)NCT04738123 · 2021-04-06 · 1 site observation

A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425 · 2021-03-30 · 1 site observation

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's PatientsNCT04350177 · 2021-02-16 · 1 site observation

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)NCT04659174 · 2021-02-01 · 1 site observation

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of SchizophreniaNCT04712734 · 2021-01-13 · 1 site observation

Relative Bioavailability of LY03010 Compared to Listed DrugNCT04922593 · 2021-01-13 · 1 site observation

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With SchizophreniaNCT04709224 · 2020-12-30 · 1 site observation

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)NCT04659161 · 2020-12-16 · 1 site observation

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)NCT04624243 · 2020-12-15 · 1 site observation

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With DepressionNCT04521478 · 2020-11-20 · 1 site observation

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderNCT04476030 · 2020-11-09 · 1 site observation

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With SchizophreniaNCT04510298 · 2020-10-15 · 1 site observation

A Study of LY3502970 in Participants With Type 2 DiabetesNCT04426474 · 2020-10-08 · 1 site observation

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT04479852 · 2020-09-30 · 1 site observation

Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)NCT04169529 · 2020-08-25 · 1 site observation

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release CapsulesNCT04567524 · 2020-08-13 · 1 site observation

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.NCT04369391 · 2020-06-18 · 1 site observation

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)NCT04442503 · 2020-06-08 · 1 site observation

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)NCT04442490 · 2020-05-12 · 1 site observation

Study of CAD-9303 in Subjects With SchizophreniaNCT04306146 · 2020-02-28 · 1 site observation

Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaNCT04268303 · 2020-01-24 · 1 site observation

Post Approval Study (PAS) of the OPTIMIZER Smart and CCM TherapyNCT03970343 · 2020-01-21 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaNCT04158687 · 2019-11-26 · 1 site observation

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaNCT04109950 · 2019-11-20 · 1 site observation

A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaNCT04136873 · 2019-10-15 · 1 site observation

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaNCT04092686 · 2019-10-14 · 1 site observation

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer SubjectsNCT04025502 · 2019-10-07 · 1 site observation

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or SchizophreniaNCT04127058 · 2019-10-07 · 1 site observation

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MSNCT03983681 · 2019-09-26 · 1 site observation

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · 2019-09-05 · 1 site observation

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderNCT04007367 · 2019-08-06 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.